Clinical relevance of NK, NKT, and dendritic cell dose in patients receiving G-CSF-mobilized peripheral blood allogeneic stem cell transplantation

J. Vela-Ojeda, M. A. García-Ruiz Esparza, E. Reyes-Maldonado, L. Jiménez-Zamudio, E. García-Latorre, M. Moreno-Lafont, I. Estrada-García, L. Montiel-Cervantes, F. Tripp-Villanueva, M. Ayala-Sánchez, L. D. García-León, J. R. Borbolla-Escoboza, H. Mayani

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

To analyze the relationship between the cellular composition of peripheral blood allografts and clinical outcome, we performed a prospective study in 45 adult patients who underwent allogeneic peripheral blood hematopoietic stem cell transplantation (HSCT) from a histocompatibility leukocyte antigen identical sibling donor for different hematological malignancies. The dose of CD34+, CD3+, CD4+, CD8+, and CD19+ lymphocytes, natural killer (NK) cells, natural killer T (NKT) cells, type 1 and type 2 dendritic cells (DC1 and DC2), as well as regulatory T (Treg) lymphocytes was analyzed. All patients were conditioned with busulphan and cyclophosphamide (BuCy2) ± VP-16 and received a short course of methotrexate and cyclosporin-A as graft-versus-host disease (GVHD) prophylaxis. Acute GVHD (aGVHD) was present in 9 of 43 (21%) patients, and chronic GVHD (cGVHD) developed in 18 of 39 (46%) patients. There was a significantly higher incidence of aGVHD in patients receiving more than 6×106/kg CD34+ cells. In univariate analysis, variables associated with better survival were as follows: a dose of less than 1.5×107/kg NKT cells and less than 1.7×106/kg DC2 for disease-free survival (DFS), and a dose of less than 3×107/kg NK cells, less than 1.5×107/kg NKT cells, less than 3×106/kg DC1, and less than 1.7×106/kg DC2 for overall survival (OS). In the Cox regression analysis, the dose of NKT cells was the only variable associated with better DFS, while the doses of NK, NKT, and CD34+ cells (less than 8×106/kg) were associated with better OS. In conclusion, different circulating cell populations, other than CD34+ cells, are also of relevance in predicting the clinical outcome after allogeneic peripheral blood HSCT. © Springer-Verlag 2005.
Original languageAmerican English
Pages (from-to)113-120
Number of pages100
JournalAnnals of Hematology
DOIs
StatePublished - 1 Feb 2006

Fingerprint

Peripheral Blood Stem Cell Transplantation
transplantation
blood cells
Natural Killer T-Cells
stem cells
Granulocyte Colony-Stimulating Factor
Dendritic Cells
Graft vs Host Disease
dosage
cells
Hematopoietic Stem Cell Transplantation
Natural Killer Cells
Disease-Free Survival
Survival
blood
Busulfan
lymphocytes
Histocompatibility Antigens
Etoposide
Hematologic Neoplasms

Cite this

Vela-Ojeda, J. ; García-Ruiz Esparza, M. A. ; Reyes-Maldonado, E. ; Jiménez-Zamudio, L. ; García-Latorre, E. ; Moreno-Lafont, M. ; Estrada-García, I. ; Montiel-Cervantes, L. ; Tripp-Villanueva, F. ; Ayala-Sánchez, M. ; García-León, L. D. ; Borbolla-Escoboza, J. R. ; Mayani, H. / Clinical relevance of NK, NKT, and dendritic cell dose in patients receiving G-CSF-mobilized peripheral blood allogeneic stem cell transplantation. In: Annals of Hematology. 2006 ; pp. 113-120.
@article{ed6640c8e90b4e6d939ba3e4422d7a76,
title = "Clinical relevance of NK, NKT, and dendritic cell dose in patients receiving G-CSF-mobilized peripheral blood allogeneic stem cell transplantation",
abstract = "To analyze the relationship between the cellular composition of peripheral blood allografts and clinical outcome, we performed a prospective study in 45 adult patients who underwent allogeneic peripheral blood hematopoietic stem cell transplantation (HSCT) from a histocompatibility leukocyte antigen identical sibling donor for different hematological malignancies. The dose of CD34+, CD3+, CD4+, CD8+, and CD19+ lymphocytes, natural killer (NK) cells, natural killer T (NKT) cells, type 1 and type 2 dendritic cells (DC1 and DC2), as well as regulatory T (Treg) lymphocytes was analyzed. All patients were conditioned with busulphan and cyclophosphamide (BuCy2) ± VP-16 and received a short course of methotrexate and cyclosporin-A as graft-versus-host disease (GVHD) prophylaxis. Acute GVHD (aGVHD) was present in 9 of 43 (21{\%}) patients, and chronic GVHD (cGVHD) developed in 18 of 39 (46{\%}) patients. There was a significantly higher incidence of aGVHD in patients receiving more than 6×106/kg CD34+ cells. In univariate analysis, variables associated with better survival were as follows: a dose of less than 1.5×107/kg NKT cells and less than 1.7×106/kg DC2 for disease-free survival (DFS), and a dose of less than 3×107/kg NK cells, less than 1.5×107/kg NKT cells, less than 3×106/kg DC1, and less than 1.7×106/kg DC2 for overall survival (OS). In the Cox regression analysis, the dose of NKT cells was the only variable associated with better DFS, while the doses of NK, NKT, and CD34+ cells (less than 8×106/kg) were associated with better OS. In conclusion, different circulating cell populations, other than CD34+ cells, are also of relevance in predicting the clinical outcome after allogeneic peripheral blood HSCT. {\circledC} Springer-Verlag 2005.",
author = "J. Vela-Ojeda and {Garc{\'i}a-Ruiz Esparza}, {M. A.} and E. Reyes-Maldonado and L. Jim{\'e}nez-Zamudio and E. Garc{\'i}a-Latorre and M. Moreno-Lafont and I. Estrada-Garc{\'i}a and L. Montiel-Cervantes and F. Tripp-Villanueva and M. Ayala-S{\'a}nchez and Garc{\'i}a-Le{\'o}n, {L. D.} and Borbolla-Escoboza, {J. R.} and H. Mayani",
year = "2006",
month = "2",
day = "1",
doi = "10.1007/s00277-005-0037-5",
language = "American English",
pages = "113--120",
journal = "Annals of Hematology",
issn = "0939-5555",
publisher = "Springer Verlag",

}

Clinical relevance of NK, NKT, and dendritic cell dose in patients receiving G-CSF-mobilized peripheral blood allogeneic stem cell transplantation. / Vela-Ojeda, J.; García-Ruiz Esparza, M. A.; Reyes-Maldonado, E.; Jiménez-Zamudio, L.; García-Latorre, E.; Moreno-Lafont, M.; Estrada-García, I.; Montiel-Cervantes, L.; Tripp-Villanueva, F.; Ayala-Sánchez, M.; García-León, L. D.; Borbolla-Escoboza, J. R.; Mayani, H.

In: Annals of Hematology, 01.02.2006, p. 113-120.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Clinical relevance of NK, NKT, and dendritic cell dose in patients receiving G-CSF-mobilized peripheral blood allogeneic stem cell transplantation

AU - Vela-Ojeda, J.

AU - García-Ruiz Esparza, M. A.

AU - Reyes-Maldonado, E.

AU - Jiménez-Zamudio, L.

AU - García-Latorre, E.

AU - Moreno-Lafont, M.

AU - Estrada-García, I.

AU - Montiel-Cervantes, L.

AU - Tripp-Villanueva, F.

AU - Ayala-Sánchez, M.

AU - García-León, L. D.

AU - Borbolla-Escoboza, J. R.

AU - Mayani, H.

PY - 2006/2/1

Y1 - 2006/2/1

N2 - To analyze the relationship between the cellular composition of peripheral blood allografts and clinical outcome, we performed a prospective study in 45 adult patients who underwent allogeneic peripheral blood hematopoietic stem cell transplantation (HSCT) from a histocompatibility leukocyte antigen identical sibling donor for different hematological malignancies. The dose of CD34+, CD3+, CD4+, CD8+, and CD19+ lymphocytes, natural killer (NK) cells, natural killer T (NKT) cells, type 1 and type 2 dendritic cells (DC1 and DC2), as well as regulatory T (Treg) lymphocytes was analyzed. All patients were conditioned with busulphan and cyclophosphamide (BuCy2) ± VP-16 and received a short course of methotrexate and cyclosporin-A as graft-versus-host disease (GVHD) prophylaxis. Acute GVHD (aGVHD) was present in 9 of 43 (21%) patients, and chronic GVHD (cGVHD) developed in 18 of 39 (46%) patients. There was a significantly higher incidence of aGVHD in patients receiving more than 6×106/kg CD34+ cells. In univariate analysis, variables associated with better survival were as follows: a dose of less than 1.5×107/kg NKT cells and less than 1.7×106/kg DC2 for disease-free survival (DFS), and a dose of less than 3×107/kg NK cells, less than 1.5×107/kg NKT cells, less than 3×106/kg DC1, and less than 1.7×106/kg DC2 for overall survival (OS). In the Cox regression analysis, the dose of NKT cells was the only variable associated with better DFS, while the doses of NK, NKT, and CD34+ cells (less than 8×106/kg) were associated with better OS. In conclusion, different circulating cell populations, other than CD34+ cells, are also of relevance in predicting the clinical outcome after allogeneic peripheral blood HSCT. © Springer-Verlag 2005.

AB - To analyze the relationship between the cellular composition of peripheral blood allografts and clinical outcome, we performed a prospective study in 45 adult patients who underwent allogeneic peripheral blood hematopoietic stem cell transplantation (HSCT) from a histocompatibility leukocyte antigen identical sibling donor for different hematological malignancies. The dose of CD34+, CD3+, CD4+, CD8+, and CD19+ lymphocytes, natural killer (NK) cells, natural killer T (NKT) cells, type 1 and type 2 dendritic cells (DC1 and DC2), as well as regulatory T (Treg) lymphocytes was analyzed. All patients were conditioned with busulphan and cyclophosphamide (BuCy2) ± VP-16 and received a short course of methotrexate and cyclosporin-A as graft-versus-host disease (GVHD) prophylaxis. Acute GVHD (aGVHD) was present in 9 of 43 (21%) patients, and chronic GVHD (cGVHD) developed in 18 of 39 (46%) patients. There was a significantly higher incidence of aGVHD in patients receiving more than 6×106/kg CD34+ cells. In univariate analysis, variables associated with better survival were as follows: a dose of less than 1.5×107/kg NKT cells and less than 1.7×106/kg DC2 for disease-free survival (DFS), and a dose of less than 3×107/kg NK cells, less than 1.5×107/kg NKT cells, less than 3×106/kg DC1, and less than 1.7×106/kg DC2 for overall survival (OS). In the Cox regression analysis, the dose of NKT cells was the only variable associated with better DFS, while the doses of NK, NKT, and CD34+ cells (less than 8×106/kg) were associated with better OS. In conclusion, different circulating cell populations, other than CD34+ cells, are also of relevance in predicting the clinical outcome after allogeneic peripheral blood HSCT. © Springer-Verlag 2005.

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=30744453033&origin=inward

UR - https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&scp=30744453033&origin=inward

U2 - 10.1007/s00277-005-0037-5

DO - 10.1007/s00277-005-0037-5

M3 - Article

SP - 113

EP - 120

JO - Annals of Hematology

JF - Annals of Hematology

SN - 0939-5555

ER -